Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier
Su Hyun Lim,Gi Taek Yee,Dongwoo Khang
DOI: https://doi.org/10.2147/ijn.s450853
IF: 7.033
2024-03-14
International Journal of Nanomedicine
Abstract:Su Hyun Lim, 1, 2 Gi Taek Yee, 3 Dongwoo Khang 1, 2, 4 1 Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea; 2 Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 21999, South Korea; 3 Department of Neurosurgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, 21565, South Korea; 4 Department of Physiology, School of Medicine, Gachon University, Incheon, 21999, South Korea Correspondence: Dongwoo Khang, Department of Physiology, School of Medicine, Gachon University, Incheon, 21999, South Korea, Tel +82 32 899 1525, Email Gi Taek Yee, Department of Neurosurgery, College of Medicine, Gil Medical Center, Gachon University, Incheon, 21565, South Korea, Tel +82-32-460-3304, Email The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor prognosis. Nanoparticle-based combinational strategies have emerged as promising modalities to overcome these barriers and enhance drug penetration into the brain parenchyma. This review discusses various nanoparticle-based combinatorial approaches that combine nanoparticles with cell-based drug delivery, viral drug delivery, focused ultrasound, magnetic field, and intranasal drug delivery to enhance drug permeability across the BBB and BTB. Cell-based drug delivery involves using engineered cells as carriers for nanoparticles, taking advantage of their intrinsic migratory and homing capabilities to facilitate the transport of therapeutic payloads across BBB and BTB. Viral drug delivery uses engineered viral vectors to deliver therapeutic genes or payloads to specific cells within the GBM microenvironment. Focused ultrasound, coupled with microbubbles or nanoparticles, can temporarily disrupt the BBB to increase drug permeability. Magnetic field-guided drug delivery exploits magnetic nanoparticles to facilitate targeted drug delivery under an external magnetic field. Intranasal drug delivery offers a minimally invasive avenue to bypass the BBB and deliver therapeutic agents directly to the brain via olfactory and trigeminal pathways. By combining these strategies, synergistic effects can enhance drug delivery efficiency, improve therapeutic efficacy, and reduce off-target effects. Future research should focus on optimizing nanoparticle design, exploring new combination strategies, and advancing preclinical and clinical investigations to promote the translation of nanoparticle-based combination therapies for GBM. Keywords: glioblastoma, blood-brain barrier, blood-tumor barrier, nanoparticle, combination strategy, ultrasound-wave, magnetic field, intranasal drug delivery Graphical The blood-brain barrier (BBB), a highly specialized and selective biological barrier that serves as the interface between the body's general blood circulation and the central nervous system (CNS). The BBB's primary function is to regulate the influx of necessary substances like nutrients and oxygen to the brain, while restricting the entry of potentially harmful compounds, including many pharmaceuticals. 1–3 Although the BBB is critical for maintaining the stable internal environment of the brain, it also poses significant challenges for treating neurological conditions, particularly brain tumors such as glioblastoma multiforme (GBM). 4–6 GBM is the epitome of malignant primary brain tumors, characterized by its aggressive behavior and dismal prognosis, with median survival lingering around 15 months post standard interventions, surgery, radiotherapy, and chemotherapy. 7 One of the major obstacles to successful treatment of glioblastoma is the limited efficacy of systemic drug delivery due to the intrinsic selectivity of the BBB and the additional blood-tumor barrier (BTB), which is formed by the abnormal vasculature and increased interstitial pressure within the tumor microenvironment. 3,8 These barriers substantially limit the effective delivery of chemotherapeutic drugs to tumor sites, leading to poor treatment outcomes. 9,10 To overcome the BBB and BTB and to improve the delivery of therapeutic agents in glioblastoma cells, various drug delivery strategies have been developed. 11,12 These strategies include exploiting natural transcytosis mechanisms, intranasal routes that bypass the BBB, and, in particular, nanoparticle (NP)-based delivery systems. 5,13 Drug delivery systems based on nanoparticles (NPs) are attracting significant attention due to their potential to improve both drug efficacy and safety. These systems offer promising advances in targeting and penetrating the complex environment -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology